Company intelligence / Profile preview

Somanta Pharmaceuticals

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Somanta's lead asset, sodium phenylbutyrate, was in Phase 2 trials for CNS and blood cancers, with orphan designations like glioblastoma multiforme. Preclinical assets targeting drug-resistant tumors and tumor vasculature showed proof-of-concept but limited published clinical data. Platform-enabled targeted activation of drugs in hypoxic tumor microenvironments. Somanta was acquired before any assets reached market approval.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeMonoclonal antibodyProdrug
Industry: Biotech

Partnerships

Virium Pharmaceuticals (for sodium phenylbutyrate)

Beyond the preview

Go deeper on Somanta Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Somanta Pharmaceuticals.

Explore the full profile